With increasing access to germline genetic testing and as indications for patients expand, particularly for therapeutic purposes in both early and advanced breast cancer, the BRCA1/2 status will be available to more and more patients, and the number of patients with germline pathogenic mutations will be higher than in the past. The gene discussed is BRCA1; the disease is breast carcinoma.